22nd Century Group appoints CEO James A. Mish to its Board of Directors

22nd Century Group, Inc.

James A. Mish, CEO since June 2020, appointed as Class II director effective January 17, 2022.
Board expanded to seven members; Mish brings expertise in plant science and regulatory approvals (FDA, EMA, EFSA).
Prior roles include leading Noramco/Purisys (cannabinoid APIs) and Ashland Specialty Ingredients.
Appointment supports upcoming commercial launches of reduced nicotine tobacco and hemp/cannabis products.
No family relationships or related transactions disclosed; compensation per prior proxy statement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James A. Mish

Director

XXII · 22nd Century Group, Inc.

Effective: 2022-01-17
Filed: January 21, 2022, 6:59 PM ET

On January 17, 2022, the Board of Directors (the “Board”) of 22nd Century Group, Inc. (the “Company”) expanded the number of directors to seven members and appointed James A. Mish, the Company’s Chief Executive Officer, to be a director on the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James A. Mish was appointed as Director at 22nd Century Group, Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 17, 2022, the Board of Directors (the “Board”) of 22nd Century Group, Inc. (the “Company”) expanded the number of directors to seven members and appointed James A. Mish, the Company’s Chief Executive Officer, to be a director on the Board, effective immediately.

View on SEC.gov

22nd Century Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-006255

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.